Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.78 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | CLK1 | P49759 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18456885 | 0.90 | SCD (0.63) | SCDLRRK2KMT2AMEN1NPC1 | |
| SCHEMBL16554294 | 0.88 | SCD (1.00) | SCDLRRK2KMT2AMEN1NPC1 | |
| SCHEMBL18456883 | 0.87 | LRRK2 (0.67) | SCDLRRK2KMT2AMEN1NPC1 | |
| SCHEMBL21753706 | 0.85 | LRRK2 (1.00) | SCDLRRK2KMT2AMEN1NPC1 | |
| SCHEMBL31243 | 0.80 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL21753691 | 0.79 | LRRK2 (1.00) | SCDLRRK2KMT2AMEN1NPC1 | |
| SCHEMBL18425979 | 0.79 | MAPT (0.81) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL16554265 | 0.78 | SCD (1.00) | SCDLRRK2KMT2AMEN1NPC1 | |
| SCHEMBL18424866 | 0.78 | MAPT (0.65) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL18456661 | 0.78 | ALDH1A1 (0.65) | SCDKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-09-30 | — | — | US | disclosed |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-06-08 | — | — | US | disclosed |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Bumham Prebys Medical Discovery Imstitute (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Bumham Prebys Medical Discovery Imstitute (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Bumham Prebys Medical Discovery Imstitute (US) | 2018-08-09 | — | — | US | disclosed |
| WO-2017019772-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2017-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | SCD 149/4885LRRK2 3250/4885KMT2A 2739/4885 |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | SCD 149/4885LRRK2 3250/4885KMT2A 2739/4885 |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | MYC, MYCBP, MLYCD | SCD 149/4885LRRK2 3250/4885KMT2A 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.